Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 701–800 of 1,045
Progestin-associated shift of meningioma mutational landscape
Peyre, M., Gaillard, S., Marcellus, C. D., Giry, M., Bielle, F., Villa, C., Boch, A., Loiseau, H., Baussart, B., Cazabat, L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx763 · Cited by 103
Sasanuma, H., Tsuda, M., Morimoto, S., Saha, L. K., Rahman, M. M., Kiyooka, Y., Fujiike, H., Cherniack, A. D., Itou, J., Callén, E., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803177115 · Cited by 110
Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer
Li, B., & Wan, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15408 · Cited by 122
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09711-4 · Cited by 112
A Survey of Machine Learning Approaches Applied to Gene Expression Analysis for Cancer Prediction
Khalsan, M., Machado, L. R., Al-Shamery, E. S., Ajit, S., Anthony, K., Mu, M., & Agyeman, M. O. (2022) · IEEE Access · doi:10.1109/access.2022.3146312 · Cited by 121
Bi, G., Liang, J., Zhao, M., Zhang, H., Jin, X. Y., Lu, T., Zheng, Y., Bian, Y., Chen, Z., Huang, Y., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.020 · Cited by 108
Deep Learning-Driven Lung Cancer Detection: Integrating Image Processing and Web-Based Visualization
Nisha, J. R., Abedin, M. J., Nahyan, N., Faruk, R., Hridi, T. E. F., & Ahammed, M. T. (2025) · IEEE International Conference on Quantum Photonics, Artificial Intelligence & Networking (QPAIN) · doi:10.1109/qpain66474.2025.11171755 · Cited by 104
“Finally, large-scale efforts such as The Cancer Genome Atlas (TCGA) [24] have offered useful molecular profile data for lung adenocarcinoma, whereas studies like Petitjean et al. [25] focused on the prognostic consequences of TP53 mutations in malignancies.”
Pangeni, R. P., Channathodiyil, P., Huen, D. S., Eagles, L., Johal, B. K., Pasha, D., Hadjistephanou, N., Nevell, O., Davies, C. L., Adewumi, A. I., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0089-x · Cited by 106
“However, conserved mutations have been identified in approximately 2 % of microsatellite instable colorectal cancers [57] and GALNT9 is also mutated, infrequently (<1 %), in astrocytoma [58] and lung tumours [59, 60] and infrequently lost through CNV in breast tumours [12, 60].”
Suh, J. H., Johnson, A., Albacker, L. A., Wang, K., Chmielecki, J., Frampton, G. M., Gay, L. M., Elvin, J. A., Vergilio, J., Ali, S. M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0030 · Cited by 112
Haslem, D. S., Norman, S. B. V., Fulde, G., Knighton, A. J., Belnap, T., Butler, A. M., Rhagunath, S., Newman, D. M., Gilbert, H., Tudor, B. P., et al. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011486 · Cited by 110
Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma
Parry, E. M., Gable, D. L., Stanley, S. E., Khalil, S. E., Antonescu, V., Florea, L., & Armanios, M. Y. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.011 · Cited by 112
Adeegbe, D. O., Liu, S., Hattersley, M. M., Bowden, M., Zhou, C. W., Li, S., Vlahos, R., Grondine, M. R., Dolgalev, I., Ivanova, E. V., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0077 · Cited by 110
A machine learning approach for somatic mutation discovery
Wood, D. E., White, J. R., Georgiadis, A., Van Emburgh, B., Parpart-Li, S., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7939 · Cited by 103
Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells
Chen, H. J., Poran, A., Unni, A. M., Huang, S. X. L., Elemento, O., Snoeck, H., & VARMUS, H. E. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181155 · Cited by 117
Seabrook, A., Harris, J. E., Velosa, S. B., Kim, E., McInerney-Leo, A. M., Dwight, T., Hockings, J. I., Hockings, N. G., Kirk, J., Leo, P. J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa957 · Cited by 118
Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
Semenkovich, N. P., Szymanski, J. J., Earland, N. J., Chauhan, P. S., Pellini, B., & Chaudhuri, A. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006284 · Cited by 124
Baumgartner, U., Berger, F., Hashemi Gheinani, A., Burgener, S. S., Monastyrskaya, K., & Vassella, E. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0781-5 · Cited by 101
Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy
Lattanzi, M. W., Lee, Y., Simpson, D., Moran, U., Darvishian, F., Kim, R. H., Hernando, E., Polsky, D., Hanniford, D., Shapiro, R. L., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy086 · Cited by 116
Volckmar, A., Leichsenring, J., Kirchner, M., Christopoulos, P., Neumann, O., Budczies, J., de Oliveira, C. M. M., Rempel, E., Buchhalter, I., Brandt, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32133 · Cited by 105
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 111
Potential role of cellular miRNAs in coronavirus-host interplay
Nersisyan, S. A., Engibaryan, N., Gorbonos, A., Kirdey, K., Makhonin, A. M., & Tonevitsky, A. (2020) · PeerJ · doi:10.7717/peerj.9994 · Cited by 107
Anatomic position determines oncogenic specificity in melanoma
Weiss, J. M., Hunter, M. V., Cruz, N. M., Baggiolini, A., Tagore, M., Ma, Y., Misale, S., Marasco, M., Simon-Vermot, T., Campbell, N. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04584-6 · Cited by 101
Alternative splicing in cancers: From aberrant regulation to new therapeutics
Song, X., Zeng, Z., Wei, H. Y., & Wang, Z. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.09.018 · Cited by 123
Systems Pharmacology: Defining the Interactions of Drug Combinations
van Hasselt, J. G. C., & Iyengar, R. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021511 · Cited by 110
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas
Hu, X., Estecio, M. R., Chen, R., Reuben, A., Wang, L., Fujimoto, J., Carrot‐Zhang, J., McGranahan, N., Ying, L., Fukuoka, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20907-z · Cited by 106
NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis
Sengupta, D., Zeng, L., Li, Y., Hausmann, S., Ghosh, D., Yuan, G., Nguyen, T. N., Lyu, R., Caporicci, M., Benitez, A. M., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.034 · Cited by 109
Kim, Y. J., Sertamo, K., Pierrard, M.-A., Mesmin, C., Kim, S.-Y., Schlesser, M., Berchem, G., & Domon, B. (2015) · Journal of Proteome Research · doi:10.1021/pr5010828 · Cited by 106
Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function
Cabanski, C. R., White, N. M. A., Dang, H. X., Silva-Fisher, J., Rauck, C. E., Cicka, D., & Maher, C. A. (2015) · RNA Biology · doi:10.1080/15476286.2015.1038012 · Cited by 99
Kidess, E., Heirich, K., Wiggin, M., Vysotskaia, V. S., Visser, B. C., Marziali, A., Wiedenmann, B., Norton, J. A., Lee, M., Jeffrey, S. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3041 · Cited by 105
A Long Noncoding RNA Regulates Sister Chromatid Cohesion
Marchese, F. P., Grossi, E., Marín-Béjar, O., Bharti, S. K., Raimondi, I., González, J., Martínez-Herrera, D. J., Athie, A., Amadoz, A., Brosh, R. M., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.031 · Cited by 107
“Cells Depleted of CONCR Show Severe Defects in Sister Chromatid Cohesion In order to gainmore insight intoCONCR function, we performed a correlation analysis using RNA-seq data from 495 samples, including normal and tumor tissues (Cancer Genome Atlas Research Network, 2014).”
Balaji, K., Vijayaraghavan, S., Diao, L., Tong, P., Fan, Y.-H., Carey, J. P. W., Bui, T. N., Warner, S. L., Heymach, J. V., Hunt, K. K., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0157 · Cited by 103
EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Yan, K.-S., Lin, C., Liao, T.-W., Peng, C.-M., Lee, S.-C., Liu, Y., Chan, W. P., & Chou, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061172 · Cited by 101
Identifying Epistasis in Cancer Genomes: A Delicate Affair
van de Haar, J., Canisius, S., Yu, M., Voest, E. E., Wessels, L. F. A., & Ideker, T. (2019) · Cell · doi:10.1016/j.cell.2019.05.005 · Cited by 99
Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition
Ding, H., Chen, Z., Wu, K., Huang, S. M., Wu, W., LeBoeuf, S. E., Pillai, R., Rabinowitz, J. D., & Papagiannakopoulos, T. Y. (2021) · Science Advances · doi:10.1126/sciadv.abk1023 · Cited by 102
“Kelch-like ECH-associated protein 1 (hereafter KEAP1 ) is the negative regulator of NRF2 and is one of the most frequently mutated genes in lung adenocarcinoma (LUAD) ( 22 , 23 ).”
He, L., Fan, Y., Zhang, Y., Tu, T.-T., Zhang, Q., Yuan, F., & Cheng, C. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12803 · Cited by 105
An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
Rodriguez, S. M. B., Kamel, A. E., Ciubotaru, G. V., Onose, G., Sevastre, A.-S., Sfredel, V., Dănoiu, S., Dricu, A., & Tătăranu, L. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311110 · Cited by 120
“Chromosomal rearrangements: studies have shown that the formation of new tyrosine kinase fusion oncoproteins is caused by numerous chromosomal rearrangements [23,107,108].”
BackgroundEarly Events in the Molecular Pathogenesis of Lung Cancer
Kadara, H. N., Scheet, P. A., Wistuba, I. I., & Spira, A. E. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0400 · Cited by 112
Lamberti, G., Spurr, L. F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L. M., Meyerson, M. L., Cherniack, A. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.017 · Cited by 98
Progress in the treatment of drug-induced liver injury with natural products
Sun, Y., Zhang, Y., Xie, L., Rong, F., Zhu, X.-Y., Xie, J., Zhou, H., & Xu, T. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106361 · Cited by 113
Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer
Inamura, K. (2017) · Cells · doi:10.3390/cells6020012 · Cited by 111
Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities
Jung, B.-J., Yoo, H.-S., Shin, S., Park, Y., & Jeon, S. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.195 · Cited by 108
Roper, N., Gao, S., Maity, T. K., Banday, A. R., Zhang, X., Venugopalan, A., Cultraro, C. M., Patidar, R., Sindiri, S., Brown, A.-L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.028 · Cited by 97
Garrido, P., Conde, E., de Castro, J., Gómez‐Román, J., Felip, E., Pijuán, L., Isla, D., Sanz, J., Paz-Ares, L. G., & López‐Ríos, F. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02218-4 · Cited by 103
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 113
Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers
Okazaki, K., Anzawa, H., Liu, Z., Ota, N., Kitamura, H., Onodera, Y., Alam, M. M., Matsumaru, D., Suzuki, T., Katsuoka, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19593-0 · Cited by 94
Machine learning application in personalised lung cancer recurrence and survivability prediction
Yang, Y., Xu, L., Sun, L., Zhang, P., & Farid, S. S. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.03.035 · Cited by 115
“The 15 selected genes (TP53, STK11, KRAS, KEAP1, EGFR, SMARCA4, CDKN2A, BRAF, RB1, PIK3CA, NF1, ERBB2, HRAS, NRAS, AKT1) for constructing the predictive model were chosen based on reports of their significance for NSCLC [35,36].”
Methodp53 governs an AT1 differentiation programme in lung cancer suppression
Kaiser, A. M., Gatto, A., Hanson, K. J., Zhao, R. L., Raj, N., Ozawa, M. G., Seoane, J. A., Bieging-Rolett, K. T., Wang, M., Li, I., et al. (2023) · Nature · doi:10.1038/s41586-023-06253-8 · Cited by 109
Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis
Sabatini, L. M., Mathews, C., Ptak, D. M., Doshi, S., Tynan, K. M., Hegde, M., Burke, T. L., & Bossler, A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.010 · Cited by 106
“Baseline mutation frequencies in lung adenocarcinoma were on the basis of the Cancer Genome Research Network’s published data.(11) Sabatini et al”
MethodA Histologic Basis for the Efficacy of SBRT to the lung
Woody, N. M., Stephans, K. L., Andrews, M., Zhuang, T., Gopal, P., Xia, P., Farver, C. F., Raymond, D. P., Peacock, C. D., Cicenia, J. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.002 · Cited by 100
Iijima, Y., Hirotsu, Y., Amemiya, K., Ooka, Y., Mochizuki, H., Oyama, T., Nakagomi, T., Uchida, Y., Kobayashi, Y., Tsutsui, T., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.004 · Cited by 99
Winters, I. P., Chiou, S.-H., Paulk, N. K., McFarland, C. D., Lalgudi, P. V., Ma, R. K., Lisowski, L., Connolly, A. J., Petrov, D. A., Kay, M. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01519-y · Cited by 94
Qin, A., Johnson, A., Ross, J. S., Miller, V. A., Ali, S. M., Schrock, A. B., & Gadgeel, S. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.014 · Cited by 96
Fang, S., Dai, Y., Mei, Y., Yang, M., Hu, L., Yang, H., Guan, X., & Li, J. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12947 · Cited by 96
Analysis of gene expression profiles of lung cancer subtypes with machine learning algorithms
Yuan, F., Lü, L., & Zou, Q. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165822 · Cited by 110
Knight, J. R. P., Alexandrou, C., Skalka, G. L., Vlahov, N., Pennel, K., Officer, L., Teodosio, A., Kanellos, G., Gay, D. M., May-Wilson, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0652 · Cited by 96
“Lung adenocarcinomas exhibit mutations in KRAS, and HNSCCs exhibit mutations in its paralogue HRAS (68)(69), with MYC expression also important in both tumor types.”
Acquired resistance mechanisms to osimertinib: The constant battle
Zalaquett, Z., Hachem, M. C. R., Kassis, Y., Hachem, S., Eid, R., Kourié, H. R., & Planchard, D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102557 · Cited by 110
König, K., Peifer, M., Fassunke, J., Ihle, M. A., Künstlinger, H., Heydt, C., Stamm, K., Ueckeroth, F., Vollbrecht, C., Bos, M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000570 · Cited by 95
Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling
Kirkpatrick, J. D., Warren, A., Soleimany, A. P., Westcott, P. M. K., Voog, J. C., Martin-Alonso, C., Fleming, H. E., Tammela, T., Jacks, T., & Bhatia, S. N. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw0262 · Cited by 96
SMARCA4/BRG1–Deficient Non–Small Cell Lung Carcinomas: A Case Series and Review of the Literature
Nambirajan, A., Singh, V., Bhardwaj, N., Mittal, S., Kumar, S., & Jain, D. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0633-oa · Cited by 106
Wu, L., Ke, L., Zhang, Z., Yu, J., & Meng, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602762 · Cited by 109
Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia
Haider, S., McIntyre, A., van Stiphout, R. G. P. M., Winchester, L. M., Wigfield, S., Harris, A. L., & Buffa, F. M. (2016) · Genome Biology · doi:10.1186/s13059-016-0999-8 · Cited by 93
Reis, H., Metzenmacher, M., Goetz, M., Savvidou, N., Darwiche, K., Aigner, C., Herold, T., Eberhardt, W., Skiba, C., Hense, J., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.010 · Cited by 97
Genetic Alterations of TRAF Proteins in Human Cancers
Zhu, S., Jin, J., Gokhale, S., Lu, A. M., Shan, H., Feng, J., & Xie, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02111 · Cited by 108
Kuna, R. S., & Field, S. J. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r088328 · Cited by 92
Lotsberg, M. L., Wnuk-Lipińska, K., Terry, S., Tan, T. Z., Lü, N., Trachsel-Moncho, L., Røsland, G. V., Siraji, M. I., Hellesøy, M., Rayford, A. J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.015 · Cited by 103
“Furthermore, the strong positive correlation between AXL expression and positive regulation of autophagy was also confirmed in a combined group of LUAD and LUSC from the TCGA cohort (LUAD + LUSC, n = 1018) 37 (Spearman correlation Rho = +0.5017, p < 1E-200).”
InfluentialUpdated Prognostic Factors in Localized NSCLC
Garinet, S., Wang, P., Mansuet‐Lupo, A., Fournel, L., Wislez, M., & Blons, H. (2022) · Cancers · doi:10.3390/cancers14061400 · Cited by 108
Berr, A. L., Wiese, K. M., dos Santos, G., Koch, C. M., Anekalla, K. R., Kidd, M. E., Davis, J. M., Cheng, Y., Hu, Y., & Ridge, K. M. (2023) · Oncogene · doi:10.1038/s41388-023-02703-9 · Cited by 112
Plenker, D., Bertrand, M., de Langen, A. J., Riedel, R. F., Lorenz, C., Scheel, A. H., Müller, J. N., Brägelmann, J., Daßler‐Plenker, J., Kobe, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3001 · Cited by 101
Hierro, C., Rodon, J. A., & Tabernero, J. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.027 · Cited by 99
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung
Hwang, D. H., Sholl, L. M., Rojas‐Rudilla, V., Hall, D. L., Shivdasani, P., Garcia, E. P., MacConaill, L. E., Vivero, M., Hornick, J. L., Kuo, F. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.010 · Cited by 98
Weeden, C. E., Ah-Cann, C., Holik, A. Z., Pasquet, J., Garnier, J.-M., Mérino, D., Lessène, G., & Asselin-Labat, M.-L. (2018) · Oncogene · doi:10.1038/s41388-018-0268-2 · Cited by 97
Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines
Vormehr, M., Türeci, Ö., & Sahin, U. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-042617-101816 · Cited by 92
Chen, H., Deng, C., Gao, J., Wang, J., Fu, F., Wang, Q., Wang, Q., Zhang, S., Zhang, S., Fan, F., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.012 · Cited by 110
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
Inamura, K., Yokouchi, Y., Kobayashi, M., Sakakibara, R., Ninomiya, H., Subat, S., Nagano, H., Nomura, K., Okumura, S., Shibutani, T., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.013 · Cited by 96
Effects of aneuploidy on gene expression: implications for cancer
Dürrbaum, M., & Štorchová, Z. (2015) · FEBS Journal · doi:10.1111/febs.13591 · Cited by 116
Zheng, W., Jiang, C., & Li, R. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s91796 · Cited by 90
Fei, D. L., Motowski, H., Chatrikhi, R., Prasad, S., Yu, J., Gao, S., Kielkopf, C. L., Bradley, R. K., & VARMUS, H. E. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006384 · Cited by 90
Zhang, M., Pang, H., Zhao, W., Li, Y., Yan, L., Dong, Z., & He, X. (2018) · BMC Cancer · doi:10.1186/s12885-018-4435-1 · Cited by 102
Improved indel detection in DNA and RNA via realignment with ABRA2
Mose, L. E., Perou, C. M., & Parker, J. S. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz033 · Cited by 91
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis
Kharbanda, A., Walter, D. M., Gudiel, A. A., Schek, N., Feldser, D. M., & Witze, E. S. (2020) · Science Signaling · doi:10.1126/scisignal.aax2364 · Cited by 98
Patient-derived cell line, xenograft and organoid models in lung cancer therapy
Huo, K.-G., D’Arcangelo, E., & Tsao, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-154 · Cited by 108
Jensen-Pergakes, K., Tatlock, J., Maegley, K. A., McAlpine, I. J., McTigue, M., Xie, T., Dillon, C. P., Wang, Y., Yamazaki, S., Spiegel, N., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0620 · Cited by 97
Targeting FSP1 triggers ferroptosis in lung cancer
Wu, K., Vaughan, A. J., Bossowski, J. P., Hao, Y., Ziogou, A., Kim, S. M., Kim, T. H., Nakamura, M. N., Pillai, R., Mancini, M. C. S., et al. (2025) · Nature · doi:10.1038/s41586-025-09710-8 · Cited by 138
“Given our observation that GPX4 was required for lung tumorigenesis in a GEMM that closely recapitulates human LUAD development and progression, we next explored whether there was clinical evidence suggesting that ferroptosis regulators in general are altered in lung cancer 40 .”
InfluentialHippo and TGF-β interplay in the lung field
Saito, A., & Nagase, T. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00238.2015 · Cited by 91
Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations
Campbell, J. D., Lathan, C. S., Sholl, L. M., Ducar, M. A., Vega, M., Sunkavalli, A., Lin, L., Hanna, M., Schubert, L., Thorner, A. R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6108 · Cited by 98
Tang, K.-J., Constanzo, J. D., Venkateswaran, N., Melegari, M., Ilcheva, M., Morales, J. C., Skoulidis, F., Heymach, J. V., Boothman, D. A., & Scaglioni, P. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2603 · Cited by 91
Air pollution and genomic instability: The role of particulate matter in lung carcinogenesis
Santibáñez-Andrade, M., Quezada-Maldonado, E. M., Osornio-Vargas, Á. R., Sánchez-Pérez, Y., & García-Cuellar, C. M. (2017) · Environmental Pollution · doi:10.1016/j.envpol.2017.06.019 · Cited by 98
Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity
Tata, P. R., Chow, R. D.-W., Saladi, S. V., Tata, A., Konkimalla, A., Bara, A. M., Montoro, D. T., Hariri, L. P., Shih, A. R., Mino-Kenudson, M. A., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.02.024 · Cited by 100
Wu, Q., Tian, Y., Zhang, J., Tong, X., Huang, H., Li, S., Zhao, H., Tang, Y., Yuan, C., Wang, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716589115 · Cited by 91
The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Saito, A., Horie, M., Micke, P., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113611 · Cited by 90
SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation
Fahey, C. C., & Davis, I. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026468 · Cited by 99
Hayashi, T., Desmeules, P., Smith, R. S., Drilon, A., Somwar, R., & Ladanyi, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2343 · Cited by 90
Self-citationDrug Resistance to EGFR Inhibitors in Lung Cancer
Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2016) · Chemotherapy · doi:10.1159/000443368 · Cited by 92
Behera, M., Owonikoko, T. K., Gal, A. A., Steuer, C. E., Kim, S., Pillai, R. N., Khuri, F. R., Ramalingam, S. S., & Sica, G. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.009 · Cited by 90
Rachiglio, A. M., Abate, R. E., Sacco, A., Pasquale, R., Fenizia, F., Lambiase, M., Morabito, A., Montanino, A., Rocco, G., Romano, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10704 · Cited by 96
Hidalgo, M. R., Çubuk, C., Amadoz, A., Salavert, F., Carbonell‐Caballero, J., & Dopazo, J. (2016) · Oncotarget · doi:10.18632/oncotarget.14107 · Cited by 105
Zhao, J., Sun, Y., Huang, Y., Song, F., Huang, Z., Bao, Y., Zuo, J., Saffen, D. W., Shao, Z., Liu, W., et al. (2017) · Scientific Reports · doi:10.1038/srep40488 · Cited by 96
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
Tseng, C., Chiang, C., Tseng, J., Yang, T., Hsu, K.-H., Chen, K., Wang, C.-L., Chen, C., Yen, S.-H., Tsai, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21842 · Cited by 104
Genome-wide identification of transcription factors that are critical to non-small cell lung cancer
Zhang, D.-L., Qu, L.-W., Ma, L., Zhou, Y., Wang, G., Zhao, X., Zhang, C., Zhang, Y., Wang, M., Zhang, M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.020 · Cited by 97
tRNA Fragments Show Intertwining with mRNAs of Specific Repeat Content and Have Links to Disparities
Telonis, A. G., Loher, P., Magee, R. G., Pliatsika, V., Londin, E. R., Kirino, Y., & Rigoutsos, I. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0789 · Cited by 99
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.